ArticleKidney medicine2026
A Rare Case of Fabry Disease Combined With Idiopathic Multicentric Castleman Disease and Membranous Nephropathy.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present case documents a 17-year-old woman patient with nephrotic syndrome who was diagnosed with Fabry disease complicated by idiopathic multicentric Castleman disease (iMCD) and membranous nephropathy. Fabry disease, an X-linked lysosomal storage disorder caused by α-galactosidase A deficiency, presents diagnostic challenges in females owing to random X-chromosome inactivation. The presence of zebra bodies in the podocytes, as well as a genetic test, confirmed the diagnosis of Fabry disease, alongside immune complex deposits, which were indicative of membranous nephropathy. In addition, the presence of multiple lymphadenopathies and elevated serum inflammatory marker levels led to the diagnosis of iMCD. Notably, the proteinuria and inflammation rapidly resolved with steroid therapy, suggesting an immune-mediated injury distinct from Fabry-related podocytopathy. This unique case of Fabry disease coexisting with iMCD and membranous nephropathy raises intriguing questions regarding the potential interplay between globotriaosylceramide (Gb3)-induced inflammation and immune dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.